Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:ABVC

ABVC BioPharma Q1 2026 Earnings Report

ABVC BioPharma logo
$1.07 -0.02 (-1.83%)
Closing price 05/18/2026 04:00 PM Eastern
Extended Trading
$1.07 0.00 (0.00%)
As of 05/18/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABVC BioPharma EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ABVC BioPharma Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 18, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

ABVC BioPharma's Q2 2026 earnings is estimated for Tuesday, May 19, 2026, based on past reporting schedules

Earnings Documents

ABVC BioPharma Earnings Headlines

ABVC BioPharma Delays Quarterly SEC Filing
ABVC BioPharma Reports 2025 Form 10-K
$30 stock to buy before Starlink goes public (WATCH NOW!)
A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.tc pixel
ABVC BioPharma Provides Corporate and Structural Update
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy.

Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.

View ABVC BioPharma Profile